Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in IgA Nephropathy
NCT07098897Phase 3Active, not recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in IgA nephropathy (IgAN), sponsored by The Affiliated Hospital of Xuzhou Medical University. Started Aug 2024; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07098897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07098897.